Inflammatory lung diseases (ILDs) are diseases characterized by acute and chronic alveolar and/or bronchial inflammation of the lung. Diseases include chronic obstructive pulmonary disease (COPD), asthma, acute lung injury (ALI), and airway infected with bacteria, viruses, or fungi.

Although the pathogenesis of these diseases has not yet been fully understood, evidence suggests that oxidative stress plays a pivotal role in ILDs. Excessive reactive oxygen species (ROS) accumulation in the airway is associated with the occurrence, progression, disease severity, and pathological changes of ILDs. Therefore, therapeutic strategies targeting oxidative stress may be useful in ILDs treatment. Although proven to be effective in preclinical and basic studies, supplementation with antioxidant agents showed limited benefits in the clinical treatment of ILDs. This is most likely due to the complexity of oxidative stress in the pathogenesis of ILDs and the inefficient drug delivery pattern in the lungs. Therefore, more studies on the mechanisms underlying oxidative stress injury and new drug delivery systems in the lungs need to be further conducted so that there are more opportunities for the treatment of ILDs in clinical settings.

This Special Issue aims to collect original research and review articles relating to current studies on oxidative stress and antioxidant strategies in ILDs. Researchers and clinicians are invited to submit articles relating to basic, translational, or clinical research. The research in question should investigate the pathophysiology of ILDs. Moreover, submissions discussing novel or repositioning drugs targeting oxidative stress for the treatment of ILDs are highly encouraged. Submissions discussing new methodologies for drug delivery (e.g., nanoparticles, liposomes, dendrimers, solid lipid nanocarriers, etc.) are also welcome.

Potential topics include but are not limited to the following:

• Cellular and molecular signals underlying oxidative stress
• The crosstalk of oxidative stress, inflammation, and immune response in ILDs
• The regulatory role of noncoding RNAs in oxidative stress
• Genomics, proteomics, and metabolomics related to oxidative stress in ILDs
• Physical and molecular biomarkers probing the redox status in lung airways
• Theoretical and bioinformatics studies on oxidative stress in ILDs
• Use of natural products with antioxidant activity for the treatment of ILDs
• Small molecules or monoclonal antibodies against oxidative stress for the treatment of ILDs
• Novel drug delivery strategies targeting oxidative stress in lungs
• Clinical or preclinical studies on monitoring and intervening redox status in ILDs